Skip to content

Clinical Effectiveness of a Motivational Interviewing-Based Conversational Mobile Application for High-Risk Drinkers

Evaluating the Clinical Effectiveness of a Motivational Interviewing-Based Conversational Mobile Application for High-Risk Drinkers

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07238998
Enrollment
220
Registered
2025-11-20
Start date
2025-12-19
Completion date
2027-04-01
Last updated
2026-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Drinking, High-Risk Drinking Patterns

Brief summary

This study aims to evaluate and compare the degree of alcohol reduction between high-risk drinkers who use a motivational interviewing-based conversational agent (chatbot) application for four weeks and those in the control group who do not use the application, in order to verify its clinical effectiveness.

Detailed description

"This study is a randomized controlled trial (RCT) employing a waitlist control design to examine the effectiveness of a motivational interviewing-based conversational mobile application for high-risk drinkers. After obtaining voluntary written consent, participants will complete a screening process that includes a clinical interview (MINI, DSM) and demographic data collection. Those who meet all inclusion criteria and none of the exclusion criteria will be randomly assigned in a 1:1 ratio to either the intervention group (n = 110) or the control group (n = 110). For the intervention group, the total study period is 16 weeks and consists of three visits (week 0, 4, and 16). The control group will participate for 20 weeks and complete four visits (week 0, 4, 16, and 20). The final follow-up assessment for both groups will be conducted via telephone and online. The intervention group will use the mobile app (chatbot) for 4 weeks beginning on the baseline assessment day (Visit 1). Re-assessments will be conducted at week 4 (Visit 2), marking the end of the intervention period, and again at week 16 (Visit 3), which occurs three months after the intervention. The control group will not receive any intervention from baseline to week 16 and will complete the same reassessments at week 4 (Visit 2) and week 16 (Visit 3). After the week 16 assessment, the control group will also use the mobile app for 4 weeks and undergo a final evaluation at week 20 (Visit 4), following completion of their intervention period. This waitlist control design allows for a rigorous comparison of outcomes between the two groups while ensuring that all participants eventually receive access to the intervention, supporting both ethical considerations and improved retention.

Interventions

BEHAVIORALMotivational Interviewing-Based Conversational Agent (Mobile Chatbot)

Participants in the experimental arm will use a motivational interviewing-based conversational agent (mobile chatbot) for 4 weeks starting on the baseline assessment day (Week 0). The intervention provides daily interactive dialogues, personalized feedback, goal-setting guidance, and behavior change strategies based on motivational interviewing principles. Participants are encouraged to complete daily sessions designed to enhance motivation, support self-monitoring, and reduce high-risk alcohol consumption.

OTHERNo Intervention (Waitlist Control)

Participants in the waitlist control arm will not receive any intervention during the primary evaluation period (Week 0-16). They will complete the same reassessments as the intervention group at Week 4 and Week 16. After the Week 16 follow-up, control arm participants will be offered the same 4-week chatbot intervention for ethical considerations, followed by a final assessment at Week 20. This post-Week-16 intervention is not included in the primary efficacy analysis.

Sponsors

Yonsei University
Lead SponsorOTHER
BlueSignum Corporation
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 59 Years
Healthy volunteers
No

Inclusion criteria

1. Individuals aged 19 to 59 years who are capable of providing valid written informed consent. 2. Individuals who meet the definition of high-risk drinking (AUDIT score ≥ 8).3.- Individuals who express a desire to reduce their alcohol consumption. 3. Individuals who own and use an Android smartphone (version 8 or higher). 4. Individuals who have no difficulty using mobile applications. 5. Individuals who are able to communicate adequately with the research team. 6. Individuals who fully understand the study procedures and voluntarily agree to participate.

Exclusion criteria

1. Individuals who are unable to read or understand the consent form (e.g., illiterate individuals, non-Korean speakers). 2. Individuals with impaired decision-making capacity. 3. Pregnant individuals or those planning to become pregnant during the study period. 4. Individuals who are currently participating in another clinical study. 5. Individuals who are receiving treatment or counseling for alcohol-related problems. 6. Individuals who use two or more mobile phones. 7. Individuals who are expected to change their mobile phone or SIM card, or who plan to travel 8. abroad during the intervention period. 8. Any individual deemed inappropriate for study participation at the discretion of the investigator.

Design outcomes

Primary

MeasureTime frameDescription
Change in Past 7-Day Alcohol Consumption (Standard Drinks and Binge Drinking Frequency) From Baseline to Week 16Week 0 (Baseline), Week 4, and Week 16Alcohol consumption during the past 7 days-including total standard drink units and binge drinking frequency-will be assessed at Week 0, Week 4, and Week 16 using validated self-report measures. The primary efficacy analysis will evaluate changes from baseline to Week 16 in both past 7-day standard alcohol consumption and past 7-day binge drinking episodes to determine the intervention's effectiveness in reducing high-risk alcohol use.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 14, 2026